{
    "id": 21505,
    "fullName": "JAK2 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "JAK2 amp indicates an increased number of copies of the JAK2 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3717,
        "geneSymbol": "JAK2",
        "terms": [
            "JAK2",
            "JTK10",
            "THCYT3"
        ]
    },
    "variant": "amp",
    "createDate": "04/22/2016",
    "updateDate": "10/01/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5947,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models with JAK2 amplification (PMID: 27075627).",
            "molecularProfile": {
                "id": 22035,
                "profileName": "JAK2 amp"
            },
            "therapy": {
                "id": 3991,
                "therapyName": "NVP-BSK805 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5204,
                    "pubMedId": 27075627,
                    "title": "Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27075627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5948,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-BSK805 inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models harboring JAK2 amplification (PMID: 27075627).",
            "molecularProfile": {
                "id": 22035,
                "profileName": "JAK2 amp"
            },
            "therapy": {
                "id": 2785,
                "therapyName": "NVP-BSK805",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5204,
                    "pubMedId": 27075627,
                    "title": "Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27075627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10923,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with SMO antagonist-resistant basal cell carcinoma with high mutational burden and harboring several genomic alterations, including amplification of PD-L1 (CD274) as well as PD-L2 (PDCD1LG2) and JAK2, demonstrated a durable response following treatment with Opdivo (nivolumab) (PMID: 27942391).",
            "molecularProfile": {
                "id": 27860,
                "profileName": "CD274 amp JAK2 amp PDCD1LG2 amp"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8932,
                    "pubMedId": 27942391,
                    "title": "Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27942391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14391,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a glioblastoma patient harboring amplifications in CD274, PDCD1LG2, JAK2, MET, and MDM2 was sensitive to the combined therapy of Opdivo (nivolumab) and Cometriq (cabozantinib), demonstrating a partial response at four weeks (PMID: 29902298).",
            "molecularProfile": {
                "id": 29995,
                "profileName": "CD274 amp JAK2 amp MDM2 amp MET amp PDCD1LG2 amp"
            },
            "therapy": {
                "id": 2067,
                "therapyName": "Cabozantinib + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11631,
                    "pubMedId": 29902298,
                    "title": "Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29902298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 22035,
            "profileName": "JAK2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27860,
            "profileName": "CD274 amp JAK2 amp PDCD1LG2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29995,
            "profileName": "CD274 amp JAK2 amp MDM2 amp MET amp PDCD1LG2 amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}